- Previously treated metastatic HER2+Breast Cancer
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)
New sub-study includes margetuximab plus chemotherapy with decreased infusion time.
- Previously treated Hormone receptor-positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)
Our Research Staff:
Principal Investigators Mikhail Shtivelband, MD, Ph.D. and Sujith Kalmadi, MD, oversee sub-investigators participating in trials that involve Ironwood Women’s Centers and Ironwood Cancer & Research Centers. For a list of our closed studies click here.